title: BW25113/pCA24N-hha LB 2 mM IPTG suspension cells

city: State College

first: Thomas

middle: K.

last: Wood

state: PA

address: Room 161 Fenske Laboratory, University Park

department: Chemical Engineering & Biochemistry and Molecular Biology

institute: Pennsylvania State University

description: RNA extracted from suspension cells of BW25113/pCA24N-hha in LB supplemented with IPTG 2 mM, that was inoculated with overnight cells to a final turbidity of 600 nm of 0.1 and grown at 37ºC with shaking (250 rpm) to a turbidity at 600 nm of 0.5

hyb_protocol: Following affymetrix protocol. Prepared hybridization cocktail for Single Probe Array (49 Format) with total 200 ul volume including 1X hybrization buffer, 50 pM B2 Control Oligo, 0.1 mg/mL Herring Sperm DNA, 0.5 mg/mL BSA, and at least 1 ug fragmented and labelled cDNA. After loading of hybridization cocktail in Affymetrix E. coli Antisense Genome Array, the hybridization was performed at 45ºC, with 60 rpm for 16 hours. After hybridization, the probe array was washed and stained using Affymetrix Genechip Fluidics Station 450 and the software GenomeChipOperating Software (GCOS).

scan_protocol: Following affymetrix protocol. After washing and staining, the probe array was scanned using Affymetrix Genechip scanner GCS3000 7G system and the software GenomeChipOperating Software (GCOS)

data_processing: MAS 5.0 Expression Analysis Default Setting

organism: Escherichia coli

source_name: Channel 1

label_protocol:
Following affymetrix protocol.
cDNA was synthesized first using Promega M-MLV Reverse transcriptase (cat# M1705). After removing RNA, DNA fragmentation was performed to obtain and 50-200 base cDNA fragments. The fragmented cDNA was labelled with Biotin-ddUTP using Enzo BioArray Terminal Labeling Kit (Affymetrix, P/N 900181).

extract_protocol: suspension cells of BW25113/pCA24N-hha were cultured in 25 mL of LB supplemented with IPTG 2 mM, that was inoculated with overnight cells to a final turbidity of 600 nm of 0.1 and grown at 37ºC with shaking (250 rpm) to a turbidity at 600 nm of 0.5,  after that the cells were collected by centrifugation and quickly frozen. The total RNA was isolated with Qiagen RNeasy mini Kit (Cat# 74104)


title: MPI-527

status: Public on Jun 17 2008

type: RNA

city: Regensburg

first: Stefan

last: Bentink

state: Bayern

address: Josef Engertstr. 9

department: Institute of Functional Genomics

country: Germany

institute: University of Regensburg

description: Mature aggressive B-cell lymphoma

hyb_protocol: Affymetrix hybridization was carried with U133A GeneChips according to the manufacturer’s recommendations. In brief, 15 microgram of Biotin-labelled and fragmented cRNA were mixed with 20x GeneChip Eukaryotic Hybridization Control (Affymetrix) and supplemented with B2 control oligonucletide, salmon sperm DNA, acetylated bovine serum albumin and hybridization buffer and water making up a total volume of 300 microliter.

scan_protocol: After hybridization of night (16 hours, 45 C) the hybridization mixture was removed from the GeneChip and washing and staining of the GeneChips was performed in a fluidics station (Affymetrix). The detection of the Biotin-labeled cRNA was mediated by a streptavidin-phycoerythrin complex. The measurement of the fluorescence intensity was carried out in an Agilent scanner (GA2500).

data_processing: Probe level normalization was done using the calibration and variance stabilization method by Huber et al. (Bioinformatics 2002, PMID: 12169536).  Probe-set summarization was performed using the median polish method on the normalized data (Irrizary et al. Nucleic Acids Research 2003, PMID: 12582260).

label: Biotin

molecule: total RNA

organism: Homo sapiens

source_name: Frozen tissue

label_protocol: For Affymetrix GeneChip hybridization, 5 microgram of total RNA was employed to generate a double-stranded cDNA with the help of the INVITROGEN Superscript kit. After removal of small molecular components (Affymetrix Clean-up Module), Biotin-labelled cRNA was synthesized by application of the ENZO Labeling kit (T7 RNA polymerase). The concentration of the produced cRNA was determined photometrically (NanoDrop) and the size range of the labelled products was evaluated by BioAnalyzer (Agilent) measurement before and after fragmentation.

extract_protocol: RNA was isolated using RNeasy Mini Kit (both from QIAGEN).The concentration was determined photometrically (NanoDrop). The quality of the RNA was assessed by analysis of an aliquot in the Agilent BioAnalyzer.

tag: Unique Identifier

tag: Age at diagnosis

tag: Sex of patient

value: female

tag: Consensus morphological diagnosis from expert hematopathologists

value: BL

tag: Immunohistochemistry

value: Proportion of positive tumor cells CD20 (>1 => pos):4

value: Proportion of positive tumor cells CD10 (>1 => pos):4

value: Proportion of positive tumor cells BCL2 (>1 => pos):0

value: Signal intensity BCL2:0

value: Percentage Ki-67 of positive tumor cells (proliferative index):95

value: Percentage of positive tumor cells CD5 (>1 => pos):0

value: Percentage of positive tumor cells BCL6 (>1 => pos):3

tag: Cytogenetics

value: Status of MYC translocation:IG-MYC

value: Breakpoint at BCL6-locus detected:neg

value: IgH-BCL2 Fusion:neg

tag: ArrayCGH

value: Complexity/relative number of genomic gains and losses:4

tag: Cytogenetics/arryCGH

value: MYC-break with simple or complex karyotype:MYC.simple

tag: Ann Arbour Stage

tag: Gene expression

value: Diagnosis according to mBL gene expression signature:mBL

tag: Germinal center like/ activated B-cell like signature

value: GCB

tag: mBL index (>0.95 => mBL)


title: BW25113/pCA24N LB 2 mM IPTG suspension cells

country: USA

description: RNA extracted from suspension cells of BW25113/pCA24N in LB supplemented with IPTG 2 mM, that was inoculated with overnight cells to a final turbidity of 600 nm of 0.1 and grown at 37ºC with shaking (250 rpm) to a turbidity at 600 nm of 0.5

label: biotin

extract_protocol: suspension cells of BW25113/pCA24N were cultured in 25 mL of LB supplemented with IPTG 2 mM, that was inoculated with overnight cells to a final turbidity of 600 nm of 0.1 and grown at 37ºC with shaking (250 rpm) to a turbidity at 600 nm of 0.5,  after that the cells were collected by centrifugation and quickly frozen. The total RNA was isolated with Qiagen RNeasy mini Kit (Cat# 74104)


title: MPI-137

description: Mature aggressive B-cell lymphoma

value: male

value: DLBCL

value: Proportion of positive tumor cells CD10 (>1 => pos):0

value: Proportion of positive tumor cells BCL2 (>1 => pos):3

value: Signal intensity BCL2:2

value: Percentage Ki-67 of positive tumor cells (proliferative index):85

value: Status of MYC translocation:neg

value: Complexity/relative number of genomic gains and losses:NA

value: MYC-break with simple or complex karyotype:MYC.neg

value: III

value: Diagnosis according to mBL gene expression signature:non-mBL


title: MPI-532

description: Mature aggressive B-cell lymphoma

value: Proportion of positive tumor cells CD20 (>1 => pos):4

value: Proportion of positive tumor cells CD10 (>1 => pos):4

value: Proportion of positive tumor cells BCL2 (>1 => pos):NA

value: Signal intensity BCL2:NA

value: Percentage Ki-67 of positive tumor cells (proliferative index):95

value: Percentage of positive tumor cells CD5 (>1 => pos):0

value: Percentage of positive tumor cells BCL6 (>1 => pos):2

value: Status of MYC translocation:IG-MYC

value: Breakpoint at BCL6-locus detected:neg

value: Complexity/relative number of genomic gains and losses:10

value: MYC-break with simple or complex karyotype:MYC.complex


title: THP1_bortezomib_resistant_100nm_minus_6months_bortezomib

status: Public on Jun 14 2008

city: Amsterdam

first: Daoud

last: Sie

address: De Boelelaan 1117

department: Pathology

country: Netherlands

institute: Vrije Universiteit Medical Center

description: See Cloos J. et al. Mol.Cancer Res. 2006;4:71-7

hyb_protocol: Labeling was performed as described in Cloos J. et al. Mol.Cancer Res. 2006;4:71-7

scan_protocol: Microarray Scanner G2505B (Agilent Technologies), default settings

data_processing: Spot analysis and feature extraction were fully automated using BlueFuse version 3.4 (BlueGnome, Cambridge, UK). Spots were excluded when the Confidence value <0.1. Subsequently, Lowess block normalization was performed within the same program on the non-flagged spots and exported to Excel (Microsoft).

growth_protocol: Cells were kept as a suspension culture in RPMI-1640 medium supplemented with 5% fetal calf serum, 20 mM HEPES, 2 mM glutamine and 100 µg/ml penicillin/streptomycin at 5% CO2 and 37oC. Cell cultures were seeded at a density of 3 x 105 cells/ml and refreshed twice weekly.

extract_protocol: RNA-Bee (according manufafcuturer's protocol)

source_name: THP-1 -BTZ100

treatment_protocol: BTZ-resistant THP1 cell lines were obtained by stepwise increasing extracellular concentrations of bortezomib over a period of 6 months, nM (IC50 concentration: 3.3 nM) up to a concentration of 100 nM bortezomib, starting at a concentration of 2.5 nM

tag: THP-1 (ATCC nr. TIB-202), human monocytic/macrophage cells made resistant up to 100 nM of bortezomib. Subsequently resistant cells were cultured in the absence of bortezomib for a period of up to 6 months.


title: THP1_bortezomib_resistant_30nm

label_protocol: Labeling was performed as described in Cloos J. et al. Mol.Cancer Res. 2006;4:71-7

source_name: THP-1 BTZ30

treatment_protocol: BTZ-resistant THP1 cell lines were obtained by stepwise increasing extracellular concentrations of bortezomib over a period of 6 months, nM (IC50 concentration: 3.3 nM) up to a concentration of 30 nM bortezomib, starting at a concentration of 2.5 nM

tag: THP-1 (ATCC nr. TIB-202), human monocytic/macrophage cells made resistant up to 30 nM of bortezomib.


title: THP1_bortezomib_resistant_100nm

source_name: THP-1 BTZ100

tag: THP-1 (ATCC nr. TIB-202), human monocytic/macrophage cells made resistant up to 100 nM of bortezomib.


title: LCL 5931

status: Public on Jun 13 2008

city: Philadelphia

first: Maja

last: Bucan

address: 415 Curie Blvd

institute: UPENN

description: Gene expression data from LCLs derived from individual GM05930/5931

hyb_protocol: standard Affymetrix procedures

scan_protocol: standard Affymetrix procedures

data_processing: Affymetrix Microarray Suite version 5.0 followed by GCRMA normalization using GeneSpring 7.2

source_name: LCL GM05931

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 5 ug total RNA.

growth_protocol: Fibroblasts and LCLs were cultured in T-25 flasks under standard condition as recommended by Coriell Institute for Medical Research.

extract_protocol: Total RNA was extracted by Trizol reagent according to the manufacturer's instructions, which is followed by cleanup using RNeasy mini kit (Qiagen).

treatment_protocol: Cells were washed twice by PBS before RNA isolation.

tag: Diagnosis

value: unaffected

tag: Age


title: LCL 5937

description: Gene expression data from LCLs derived from individual GM05936/5937

source_name: LCL GM05937


title: LCL 5935

description: Gene expression data from LCLs derived from individual GM05934/5935

source_name: LCL GM05935

value: bipolar type I


title: LCL 5933

description: Gene expression data from LCLs derived from individual GM05932/5933

source_name: LCL GM05933


title: Dauer

status: Public on Jun 16 2008

city: San Francisco

first: James

middle: Graham

last: Ruby

state: CA

address: 1700 4th Street QB3 s404

department: Biochemistry

institute: UCSF

description: PCR products generated for all the samples described above were sequenced on a Solexa sequencing platform (Illumina, Inc.) (Seo et al., 2004).

hyb_protocol: not applicable

scan_protocol: not applicable

data_processing: 5p end defined by start of tag, 3p end defined by 6nt perfect match to 3p linker

label: not applicable

organism: Caenorhabditis elegans

source_name: Dauer L3, whole worms

label_protocol: not applicable

extract_protocol:
5p monophosphate, 3p hydroxyl-dependent ligations
Short endogenous C. elegans RNAs from egg, L1, L2, L3, L4, dauer, mixed-stage, and glp-4 young adults were cloned using a protocol derived from (Lau et al., 2001). Total RNA was combined with trace amounts of 5’-32P-labeled RNA standards, AGC GUG UAG GGA UCC AAA and GGC AUU AAC GCG GCC GCU CUA CAA UAG UGA, 18 and 30 nt in length, respectively. RNA was resolved on a 15% polyacrylamide, 8M urea gel, and the gel fragment spanning both RNA standards was excised. RNA was eluted and ethanol-precipitated using 15mg of glycogen as the carrier. The gel-purified RNA was incubated with 10mM pre-adenylated 3’-adaptor oligonucleotide, 1.5 U/mL Rnl2(1-249) (Ho et al., 2004) in 10mL ligation buffer (50mM HEPES pH 8.3, 10mM MgCl2, 10mg/mL BSA, 8.3% glycerol) at 22°C for 30 minutes. The 3’-ligation reaction was purified on a 15% gel. For the 5’-ligation, 3’-ligated products were incubated with 40mM 5’ adaptor oligonucleotide, 267mM ATP, and 1.3U/mL T4 ligase (Promega) in 15mL ligation buffer at 22°C for 18+ hours. The ligated products were purified on a 10% gel, reverse transcribed in a standard 30mL reaction (SuperScript II, Invitrogen) with the RT primer. RNA was base-hydrolyzed with 5mL of 1M NaOH by incubating at 90°C for 10 minutes, and the reaction was neutralized with 25mL of 1M HEPES pH 7.0 and desalted with Microspin G-25 (Amersham). The cDNA was extended and amplified by SOE-PCR, using the RT primer and 3’-long primer. The PCR product was gel-purified on a 90% formamide, 8% acrylamide gel.

tag: The Bristol strain N2 was used as the standard wild-type strain. The mutant allele used in this study was glp-4(bn2). C. elegans culture and genetics were as described in (Brenner, 1974).


title: L1

source_name: L1, whole worms


title: Glp-4 mutant

source_name: glp-4 adult, whole worms


title: fibroblast 5936

description: Gene expression data from fibroblasts derived from individual GM05936/5937

source_name: Fibroblast GM05936


title: fibroblast 5934

description: Gene expression data from fibroblasts derived from individual GM05934/5935

source_name: Fibroblast GM05934


title: Adult (A)

source_name: Adult, whole worms


title: fibroblast 5932

description: Gene expression data from fibroblasts derived from individual GM05932/5933

source_name: Fibroblast GM05932


title: L2

source_name: L2, whole worms


title: CRUSH 7D C

city: MURCIA

first: MARTA

last: AGUDO

address: FACULTAD MEDICINA, CAMPUS ESPINARDO

department: OFTALMOLOGY

country: Spain

institute: MURCIA UNIVERSITY

description: RNA from retinas 7d post IONC rep 3

hyb_protocol: Following fragmentation, 15 ug of cRNA were hybridized on Rat norvergicous Affymetrix GeneChip Rat Genome 230 2.0 Array

scan_protocol: Gene Chip Operating software, (GCOS 1.3 Afffymetrix, Santa Clara CA)

data_processing: Data were processing using Bioconductor software, normalization was done with the GCRMA package. IONT and IONC samples at each time point were compared to naive ones. Significantly regulated sequences were extracted using the limma package  (Bvalue>0, pvalueFDR<0,01) and the maSigPro package for time course series (pvalueFDR<0,01, Rsquared treshold=0,6).Log2 output values of regulated sequences were transformed to their net (fold change) values. Control level of expresion was set to 1, above 1 are up-regulated sequences and below 1 to 0 downregulated (when a RNA is not present its value is not negative but 0).

organism: Rattus norvegicus

source_name: retinas 7d post IONC

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 5 ug total RNA (Expression Analysis Technical Manual, 2003, Affymetrix).

growth_protocol: Rats were kept  in standard housing condintions

extract_protocol: Trizol extraction of total RNA was performed according to the manufacturer's instructions and was following by a further cleansing step through RNAeasy mini kit columns (Quiagen)

treatment_protocol: naive rats were not treated. IONT rats underwent introorbital nerve transection, IONC rats intraorbital nerve crush

tag: time and injury 7d post  IONC


title: CRUSH 3D C

description: RNA from retinas 3d post IONC rep 3

source_name: retinas 3d post IONC

tag: time and injury 3d post  IONC


title: CRUSH 3D A

description: RNA from retinas 3d post IONC rep 1


title: L3

source_name: L3, whole worms


title: fibroblast 5930

description: Gene expression data from fibroblasts derived from individual GM05930/5931

source_name: Fibroblast GM05930


title: CRUSH 48H C

description: RNA from retinas 48h post IONC rep 3

source_name: retinas 48h post IONC

tag: time and injury 48h post  IONC


title: CRUSH 7D A

description: RNA from retinas 7d post IONC rep 1


title: HeLa expression profile

type: mixed

city: Boston

first: Peter

last: Kharchenko

state: MA

address: 10 Shattuck St.

department: DBMI

institute: Harvard Medical School

description: mRNA/cDNA from HeLa S3 cells hybridized against MNase-digested bare genomic DNA.

hyb_protocol: Nimblegen Hybridization protocol (http://www.nimblegen.com)

scan_protocol: Arrays were scanned using AXON 5uM scanner

data_processing: Calculated log2 intensity ratios from raw intensity values

source_name: HeLa S3 cDNA

label_protocol: Nimblegen ChIP labeling protocol (http://www.nimblegen.com)

extract_protocol: Total RNA was isolated using TRIzol (Invitrogen). The RNA was treated with DNaseI (Roche) before 2ug of each was used to generate cDNA with the Superscript III kit (Invitrogen). Random hexamers were used to prime the cDNA synthesis. The cDNA was purified with phenol chloroform isoamyl alcohol and precipitated before being sent to Nimblegen to be analyzed for gene expression.

tag: 31 year old female epithelial cells from cervix; HeLa S3 cells mRNA/cDNA

molecule: genomic DNA

source_name: HeLa S3 gDNA

extract_protocol: see manuscript

tag: 31 year old female epithelial cells from cervix; HeLa S3 cells gDNA


title: CRUSH 48H A

description: RNA from retinas 48h post IONC rep 1


title: CRUSH 24H A

description: RNA from retinas 24h post IONC rep 1

source_name: retinas 24h post IONC

tag: time and injury 24h post  IONC


title: CRUSH 48H B

description: RNA from retinas 48h post IONC rep 2


title: CRUSH 12H C

description: RNA from retinas 12h post IONC rep 3

source_name: retinas 12h post IONC

tag: time and injury 12h post  IONC


title: CRUSH 7D B

description: RNA from retinas 7d post IONC rep 2


title: L4

source_name: L4, whole worms


title: CRUSH 24H C

description: RNA from retinas 24h post IONC rep 3


title: Embryo

source_name: Embryo, whole worms


title: CRUSH 24H B

description: RNA from retinas 24h post IONC rep 2


title: CRUSH 12H B

description: RNA from retinas 12h post IONC rep 2


title: AXO 15D A

description: RNA from retinas 15d post IONT rep 1

source_name: retinas 15d post IONT

tag: time and injury 15d post  IONT


title: AXO 7D C

description: RNA from retinas 7d post IONT rep 3

source_name: retinas 7d post IONT

tag: time and injury 7d post  IONT


title: Fog-2 mutant

source_name: fog-2 adult, whole worms

growth_protocol: Synchronous populations of animals were grown on NGM plates, with OP50 E. coli at a density of approximately 90,000 animals per 15 cm Petri dish, and harvested at specific stages of development.

extract_protocol:
5p monophosphate, 3p hydroxyl-dependent ligations
The harvested animals were washed three times with M9 buffer and incubated for 30 minutes in M9 buffer to remove the bacteria from gut.  The incubation was followed by three washes with M9 buffer. A last wash was performed with cold protein lysis buffer (30 mM HEPES-KOH [pH7.4], 2mM magnesium acetate, 100 mM potassium acetate) and the pellet frozen in a dry ice and ethanol bath. The frozen pellets were kept at – 80 ºC. The frozen pellet was ressuspended in ice-cold buffer 1:1 (v/v) containing 2mM DTT, 0.1% Igepal CA 630 (Fluka), 4x concentration Complete proteinase inhibitor (Roche) and 1% (v/v) SUPERase-IN (Ambion) and homogenized using a stainless steel Dounce homogenizer (Wheaton Incorporated). The homogenized extract was clarified by a centrifugation at 13,817 x g for 20 min at 4C. For RNA extraction, the last wash was performed using sterile water and animals were frozen in TRI Reagent (MRC, Inc.).  Worms were homogenized in a glass dounce and total RNA was isolated accordingly to the TRI Reagent protocol.
Small endogenous RNAs from prg-1(tm872), fog-2(q71), and wild-type control worms (cultured in parallel) were cloned as follows. Small RNA fractions (purified using the mirVana kit from Ambion, as described above) from both strains were resolved in a 15% polyacrylamide, 7M Urea Gel along with 10 pmol of RNA standards (GGC GTG TAG GGA TCC AAA and GGC CAA CGU UCU CAA CAA TAG TG), 18 and 24 nucleotides respectively, in separate lanes. Ethidium Bromide staining was used to visualize the RNA standards. A gel fragment was excised in the sample lanes between the two standards. RNA was eluted from the gel fragment in a [0.3M NaCl-TE (pH7.5), with 1x RNASecure (Ambion)] solution overnight and ethanol-precipitated using 10 mg of glycogen as the carrier. The gel purified RNA and 1µM of each standard were incubated with 20 µM of 3’-end linker, 1 Unit/µl of SuperRNaseIN (Ambion), 10% DMSO and 3 Units/µl RNAligase (GE Healthcare) in 10µl ligation buffer (50mM Tris-Cl pH7.5, 10mM MgCl2, 60mg/mL BSA, 10mM DTT). The 3’ end ligation was purified as in the previous step and incubated with 10µM of 5’ adapter oligonucleotide, 1 mM ATP, 1 Unit/µl SuperRNaseIN (Ambion) and 1.5 Unit/µl of T4 RNA ligase (GE Healthcare) in ligation buffer. The ligated products were purified as described above and reverse transcribed in a standard 20µl reaction (SuperScript III, Invitrogen) and subjected to RNaseH treatment. The cDNA was amplified by PCR and purified in a 10% acrylamide gel.

tag: The Bristol strain N2 was used as the standard wild-type strain. The mutant alleles used in this study were prg-1(tm872) and fog-2(q71). C. elegans culture and genetics were as described in (Brenner, 1974).


title: K562 expression profile

description: mRNA/cDNA from K562 cells hybridized against MNase-digested bare genomic DNA.

source_name: K562 cDNA

tag: 53 year old female derived chronic myuelogenous leukemia cells; human K562

source_name: K562 gDNA


title: CRUSH 3D B

description: RNA from retinas 3d post IONC rep 2


title: Mixed stage

source_name: mixed-stage, whole worms


title: AXO 7D B

description: RNA from retinas 7d post IONT rep 2


title: AXO 3D B

description: RNA from retinas 3d post IONT rep 2

source_name: retinas 3d post IONT

tag: time and injury 3d post  IONT


title: Prg-1 mutant (B)

source_name: prg-1 adult, whole worms


title: AXO 3D A

description: RNA from retinas 3d post IONT rep 1


title: AXO 48H A

description: RNA from retinas 48h post IONT rep 1

source_name: retinas 48h post IONT

tag: time and injury 48h post  IONT


title: Adult (C)

data_processing: 5p end defined by start of tag plus extraction of triple G, 3p end defined by 6nt perfect match to 3p linker

source_name: Adult, whole worms

extract_protocol:
5p end-independent, 3p hydroxyl-dependent ligations
The harvested animals were washed three times with M9 buffer and incubated for 30 minutes in M9 buffer to remove the bacteria from gut.  The incubation was followed by three washes with M9 buffer. A last wash was performed with cold protein lysis buffer (30 mM HEPES-KOH [pH7.4], 2mM magnesium acetate, 100 mM potassium acetate) and the pellet frozen in a dry ice and ethanol bath. The frozen pellets were kept at – 80 ºC. The frozen pellet was ressuspended in ice-cold buffer 1:1 (v/v) containing 2mM DTT, 0.1% Igepal CA 630 (Fluka), 4x concentration Complete proteinase inhibitor (Roche) and 1% (v/v) SUPERase-IN (Ambion) and homogenized using a stainless steel Dounce homogenizer (Wheaton Incorporated). The homogenized extract was clarified by a centrifugation at 13,817 x g for 20 min at 4°C. For RNA extraction, the last wash was performed using sterile water and animals were frozen in TRI Reagent (MRC, Inc.).  Worms were homogenized in a glass dounce and total RNA was isolated accordingly to the TRI Reagent protocol.
Small RNA library was constructed as described in (Ambros, et al, 2003), with the exception that the Reverse Transcriptase used was Invitrogen SuperScript II.

tag: The Bristol strain N2 was used as the standard wild-type strain. The mutant allele used in this study was prg-1(tm872).  C. elegans culture and genetics were as described in (Brenner, 1974).


title: 20um Anacardic acid treated for 12 h Replicate 3

city: Rockville

first: Tetsuya

last: Furuya

state: MD

institute: National Institutes of Health

description:
Same amount of labeled cDNA from treated parasites or untreated control was mix together
Pfab-11-21
mAdb ID: 84870

hyb_protocol: To 28 microliter buffer (30 mM sodium citrate, 300 mM sodium chloride, 50% formamide, 0.4% SDS, pH 7.0) at 42 deg. C.,was added 25 microliter of each sample of labeled cDNA along with 3 microliter of 1:1 salmon sperm/tRNA blocker (concentration?). After heating for 2 min at 98 deg. C, centrifugation for 3 min at 14,000 x g, 56 microliter of supernatant was transferred into a microarray hybridization chamber (MAUI FL Mixer, Biomicro Systems). After overnight hybridization at 45 deg. C, chambers were inserted into a jig and submerged in Buffer A, comprised of 1X SSC and 0.05% SDS. The MAUI Mixer lid was removed and the microarray slides were placed in a rack submerged in fresh Buffer A. Once all the slides were in the rack, they were washed three times in fresh buffer A, shaking 2 min for each wash. Then the slides were transferred and washed three times in fresh 0.1X SSC buffer, shaking 2 min per wash followed by centrifugation for 5 min at  580 RPM. Once dry, the slides were removed from the centrifuge and scanned on a GenePix 4000B Scanner (Axon Instruments/Molecular Devices).

scan_protocol: Scanned on a GenePix 4000B scanner.

data_processing: Images were quantified using GenePix Pro 6. Signal calculation: Median Intensity minus Median Background. Normalization: 50th percentile using spot filtered genes. Spot Filter Options: Include spots not flagged bad or not found and both Chan A and Chan B signal >= 2 SD above background. Within array multiple occurrences of Well ID were reduced to a single instance by selecting the one with the strongest signal.

organism: Plasmodium falciparum

source_name: AA treated parasites

label_protocol: Fluorescence labeling with dUTP-Cy3 or dUTP-Cy5 was performed by reverse transcription using 30 µg of total RNA with both oligo(dT)12-20 and random hexamers according to the manufacturer’s instruction (Amersham).

growth_protocol: Parasites were cultured in human O+ erythrocytes at 5% hematocrit in RPMI 1640 supplemented with 25 mM Hepes, pH 7.5, 25 mM sodium bicarbonate, 50 mg/L hypoxanthine, 0.5% Albumax II, and 40 µg/ml gentamicin sulfate. Cultures were maintained at 37oC in a gas mixture of 5% CO2 and 3% O2. Synchronization was carried out by two 5% sorbitol treatments of ring-stage parasites

extract_protocol: RNA was isolated from control and treated parasites using TRIzol Reagent and treated with RNase free DNase I (Promega, Madison, WI) to remove contaminating genomic DNA.

treatment_protocol: 3*10^9 18 h old synchronized ring were treated for 12 h with 0, 5, 10, or 20 μM of Anacardic acid

tag: strain

source_name: AA untreated control


title: AXO 48H C

description: RNA from retinas 48h post IONT rep 3


title: AXO 24H A

description: RNA from retinas 24h post IONT rep 2

source_name: retinas 24h post IONT

tag: time and injury 24h post  IONT


title: AXO 7D A

description: RNA from retinas 7d post IONT rep 1


title: AXO 12H C

description: RNA from retinas 12h post IONT rep 3

source_name: retinas 12h post IONT

tag: time and injury 12h post  IONT


title: AXO 48H B

description: RNA from retinas 48h post IONT rep 2


title: 20um Anacardic acid treated for 12 h Replicate 1

description:
Same amount of labeled cDNA from treated parasites or untreated control was mix together
Pfab-11-19
mAdb ID: 84861


title: AXO 24H B

description: RNA from retinas 24h post IONT rep 1


title: 20um Anacardic acid treated for 12 h Replicate 2

description:
Same amount of labeled cDNA from treated parasites or untreated control was mix together
Pfab-11-20
mAdb ID: 84863


title: 10um Anacardic acid treated for 12 h Replicate 3

description:
Same amount of labeled cDNA from treated parasites or untreated control was mix together
Pfab-11-18
mAdb ID: 84857


title: AXO 12H B

description: RNA from retinas 12h post IONT rep 2


title: 10um Anacardic acid treated for 12 h Replicate 2

description:
Same amount of labeled cDNA from treated parasites or untreated control was mix together
Pfab-11-17
mAdb ID: 84859


title: AXO 12H A

description: RNA from retinas 12h post IONT rep 1


title: NAIVE E

description: RNA from naive adult rat retina rep 5

source_name: naive adult rat retina

tag: naive


title: Input

extract_protocol: 5p end-independent, 3p hydroxyl-dependent ligations

tag: The Bristol strain N2 was used as the standard wild-type strain.  C. elegans culture and genetics were as described in (Brenner, 1974).

tag: IP input sample


title: 5um Anacardic acid treated for 12 h Replicate 3

description:
Same amount of labeled cDNA from treated parasites or untreated control was mix together
Pfab-11-11
mAdb ID: 84849


title: 5um Anacardic acid treated for 12 h Replicate 1

description:
Same amount of labeled cDNA from treated parasites or untreated control was mix together
Pfab-11-09
mAdb ID: 84845


title: Prg-1 mutant (C)


title: NAIVE A

description: RNA from naive adult rat retina rep 1


title: PRG-1 co-IP

extract_protocol:
5p end-independent, 3p hydroxyl-dependent ligations
To generate small RNA libraries from PRG-1 complexes, PRG-1 IPs were performed on 70mg of total wild type protein as described above. Total RNA was extracted from a fraction of worms equivalent to the one used for the PRG-1 IPs. Small RNA library was constructed as described in (Ambros, et al, 2003), with the exception that the Reverse Transcriptase used was Invitrogen SuperScript II.

tag: PRG-1 co-IP

tag: Imunoprecipitation of PRG-1 containing protein complexes was preformed by pre-clearing worm extracts with 20µl of Protein A/G PLUS-Agarose (Santa Cruz Biotechnologies) beads per 5 mg of total protein for 45 minutes at 4°C. The cleared extract was then incubated with

value: 10 µg of monoclonal antibody anti-AFP 3E6 (Qbiogene) or 15 µg of the PRG-1 specific antibody, for 1h at 4OC followed by 50 µl of Protein A/G PLUS-Agarose beads. The agarose beads were then washed three times with ice-cold lisys buffer.  RNA was extracted from the Protein A/G PLUS-Agarose beads with TRI Reagent.


title: NAIVE C

description: RNA from naive adult rat retina rep 3


title: CRUSH 12H A

description: RNA from retinas 12h post IONC rep 1

source_name: retinas 12h post IONC


title: Adult (B)


title: AXO 15D B

description: RNA from retinas 15d post IONT rep 2


title: 5um Anacardic acid treated for 12 h Replicate 2

description:
Same amount of labeled cDNA from treated parasites or untreated control was mix together
Pfab-11-10
mAdb ID: 84848


title: 48hr_No.5

status: Public on Jun 12 2008

city: New Haven

first: Zareen

last: Gauhar

state: CT

address: 333 Cedar St, 386 NSB

department: Genetics

institute: Yale

description: cells were grown from 0.5 million/ml for 48hr., start from here (start point 0hr), add ecdysone (0.5uM) treat for 48hr, compare expression profile of these treated cells to that of untreated cells (0hr cells).

hyb_protocol: As described in Sun, L.V. etal PNAS 2003

data_processing: Data processing VALUE is log2 (CY3/CY5; ref/exp)

molecule: polyA RNA

organism: Drosophila melanogaster

source_name: REF

label_protocol: The mRNA was labeled with ith Cy3/5 using SuperScript (Invitrogen).

extract_protocol: Total RNA was extracted with Trizol (Invitrogen) and mRNA was prepared with oligo-dT cellulose (Ambion).

tag: RNA from cells grown from 0.5 million/ml for 48hr. without ecdysone treatment

source_name: EXP

tag: RNA from cells grown from 0.5 million/ml for 48hr. and then under ecdysone (0.5uM) 48hr


title: 48hr_No.4

scan_protocol: As described in Sun, L.V. etal PNAS 2003


title: 48hr_No.1

data_processing: Data processing VALUE is log2 (CY5/CY3; exp/ref)


title: Control_No.2

description: cells were grown from 0.5 million/ml for 48hr., start from here (start point 0hr), grow cells for another 48hr (no ecdysone treatment), compare expression profile of these untreated cell to untreated cells at 0hr.

tag: RNA from cells grown from 0.5 million/ml for 48hr. and then grow for another 48 hours without ecdysone treatment


title: Control_No.1


title: litter 1, P60 V1 Litter 4A

city: Brighton

first: alvin

last: lyckman

address: 736 Cambridge St

institute: St Eliz Med Ctr

description: Gene expression data mouse visual cortex

hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on MGU74v2 ABC genechips. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.

scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.

data_processing: The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 500.

organism: Mus musculus

source_name: Mouse visual cortex P60 litter 4

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).

growth_protocol: standard rearing

extract_protocol: Trizol extraction of total RNA was performed according to the manufacturer's instructions.

tag: 129/SvEv, P60, mixed gender


title: NAIVE B

description: RNA from naive adult rat retina rep 2


title: 48hr_No.2


title: 48hr_No.3


title: litter 1, P60 V1 Litter 3A

source_name: Mouse visual cortex P60 litter 3


title: Control_No.4


title: Control_No.3


title: 24hr_No.4

description: cells were grown from 0.5 million/ml for 48hr., start from here (start point 0hr), add ecdysone (0.5uM) treat for 24hr, compare expression profile of these treated cells to that of untreated cells (0hr cells)

tag: RNA from cells grown from 0.5 million/ml for 48hr. and then under ecdysone (0.5uM) 24hr


title: litter 1, P60 V1 Litter 1A

source_name: Mouse visual cortex P60 litter 1


title: litter 1, P60 V1 Litter 2A

source_name: Mouse visual cortex P60 litter 2


title: Genetic interactions involving the hda3 query mutation

type: genomic

city: Baltimore

first: Daniel

last: Yuan

address: 733 N. Broadway, Suite 351

department: Molecular Biology and Genetics

institute: Johns Hopkins Univ School of Medicine

description: Matched comparison of the viability of hda3 xxxN vs xxxN cells

hyb_protocol: Labeled extracts were hybridized overnight to microarray slides at 42 degrees C. See PubMed ID 15994458.

scan_protocol: Images were acquired with a GenePix 4000B scanner.

data_processing: Paired image files were analyzed with the GenePix Pro software package (MDS Analytical Technologies, version 5.1). Feature intensities were quantified as the 'F532 Median - B532' or 'F635 Median - B635' values. The two channels were compared using the log2 ratio. Global intensity normalization factors were specific to the type of gene-specific probe (UpTag or DnTag) and were calculated as the log2 ratio of total signal intensity in features 1:6018 (UpTag) or 10972:16989 (DnTag). Ratios were ignored when intensities of the control features [635] were less than 400.

organism: Saccharomyces cerevisiae

source_name: Cells selected for the query mutation

label_protocol: UpTag and DnTag sequences were amplified from genomic DNA by asymmetric PCR using labeled primers. See PubMed ID 15994458.

growth_protocol:
Growth medium: -Ura (SC-His, -Leu-Arg+Canavanine+G418)
Growth temperature: 30 degrees C

extract_protocol: Genomic DNA was prepared by extraction with phenol-chloroform and ethanol-precipitated. See PubMed ID 15525520.

tag: Query mutation

source_name: A matched aliquot of cells, grown in parallel but without selection for the query mutation

growth_protocol:
Growth medium: +Ura (SC-His, -Leu-Arg+Canavanine+G418)
Growth temperature: 30 degrees C


title: 24hr_No.3


title: litter 1, P28 V1 Litter 1A

source_name: Mouse visual cortex P28 litter 1

tag: 129/SvEv, P28, mixed gender


title: 24hr_No.2


title: Genetic interactions involving the esa1-Hm1 query mutation at 30 degrees C

description: Matched comparison of the viability of esa1-Hm1 xxxN vs xxxN cells at 30 degrees C

growth_protocol:
Growth medium: +Nourseothricin (SC-His, -Leu-Arg+Canavanine+G418, -Ura)
Growth temperature: 30 degrees C

value: esa1-delta::natMX with esa1-Hm1 (hypomorphic allele) in URA3 CEN plasmid

growth_protocol:
Growth medium: -Nourseothricin (SC-His, -Leu-Arg+Canavanine+G418, -Ura)
Growth temperature: 30 degrees C


title: litter 1, P14 V1 Litter 2A

source_name: Mouse visual cortex P14 litter 2

tag: 129/SvEv, P14, mixed gender


title: litter 1, P28 V1 Litter 2A

source_name: Mouse visual cortex P28 litter 2


title: 12hr_No.4

description: cells were grown from 0.5 million/ml for 48hr., start from here (start point 0hr), add ecdysone (0.5uM) treat for 12hr, ompare expression profile of these treated cells to that of untreated cells (0hr cells)

tag: RNA from cells grown from 0.5 million/ml for 48hr. and then under ecdysone (0.5uM) 12hr


title: litter 1, P60 V1 Litter 4C


title: 12hr_No.5


title: 12hr_No.3


title: 24hr_No.1


title: litter 1, P60 V1 Litter 3C


title: litter 1, P28 V1 Litter 3A

source_name: Mouse visual cortex P28 litter 3


title: 12hr_No.2


title: 6hr_No.4

description: cells were grown from 0.5 million/ml for 48hr., start from here (start point 0hr), add ecdysone (0.5uM) treat for 6hr, compare expression profile of these treated cells to untreated cells (0hr cells).

tag: RNA from cells grown from 0.5 million/ml for 48hr. and then under ecdysone (0.5uM) 6hr


title: litter 1, P60 V1 Litter 2C


title: 6hr_No.5


title: litter 1, P14 V1 Litter 3A

source_name: Mouse visual cortex P14 litter 3


title: 12hr_No.1

description: cells were grown from 0.5 million/ml for 48hr., start from here (start point 0hr), add ecdysone (0.5uM) treat for 12hr, compare expression profile of the treated cells to untreated cells (0hr cells)


title: litter 1, P14 V1 Litter 1A

source_name: Mouse visual cortex P14 litter 1


title: 6hr_No.2


title: 6hr_No.3


title: litter 1, P14 V1 Litter 3C


title: NAIVE D

description: RNA from naive adult rat retina rep 4


title: litter 1, P28 V1 Litter 1C


title: litter 1, P14 V1 Litter 2C


title: 3hr_No.5

description: cells were grown from 0.5 million/ml for 48hr., start from here (start point 0hr), add ecdysone (0.5uM) treat for 3hr, compare expression profile of these treated cell to that of untreated cells (0hr cells).

tag: RNA from cells grown from 0.5 million/ml for 48hr. and then under ecdysone (0.5uM) 3hr


title: 3hr_2


title: litter 1, P28 V1 Litter 3C


title: litter 1, P60 V1 Litter 1C


title: litter 1, P28 V1 Litter 2C


title: litter 1, P60 V1 Litter 4B


title: litter 1, P60 V1 Litter 3B


title: No.4

description: cells were grown from 0.5 million/ml for 48hr., start from here (start point 0hr), add ecdysone (0.5uM) treat for 1hr, compare expression profile of these treated cells to untreated cells (0hr cells).

tag: RNA from cells grown from 0.5 million/ml for 48hr. and then under ecdysone (0.5uM) 1hr


title: 24hr_No.5


title: litter 1, P28 V1 Litter 3B


title: litter 1, P60 V1 Litter 1B


title: No.2

hyb_protocol: as described in Sun, L.V. etal PNAS 2003


title: 3hr_No.4


title: No.1


title: litter 1, P14 V1 Litter 2B


title: litter 1, P28 V1 Litter 1B


title: litter 1, P14 V1 Litter 3B


title: 3hr_1


title: litter 1, P14 V1 Litter 1B


title: litter 1, P28 V1 Litter 2B


title: litter 1, P60 V1 Litter 2B


title: 6hr_No.1


title: Mutant Replicate C

city: Stanford

first: Greg

last: Barsh

address: Beckman Center B271A

institute: Stanford University

description: see Strehlow et al. HMG 16:391 (2007)

hyb_protocol: see Strehlow et al. HMG 16:391 (2007)

scan_protocol: see Strehlow et al. HMG 16:391 (2007)

data_processing: see Strehlow et al. HMG 16:391 (2007)

label: see Strehlow et al. HMG 16:391 (2007)

source_name: Footpad epidermis

label_protocol: see Strehlow et al. HMG 16:391 (2007)

extract_protocol: see Strehlow et al. HMG 16:391 (2007)


title: Mutant Replicate A

description: see Strehlow et al. HMG 16:391 (2007)

source_name: Footpad epidermis RNA


title: 10um Anacardic acid treated for 12 h Replicate 1

description:
Same amount of labeled cDNA from treated parasites or untreated control was mix together
Pfab-11-12
mAdb ID: 84851

source_name: AA treated parasites

tag: strain

source_name: AA untreated control


title: Non-mutant Replicate B

description: see Strehlow et al. HMG 16:391 (2007)

source_name: Footpad Epidermis


title: Non-mutant Replicate A

description: see Strehlow et al. HMG 16:391 (2007)


title: Mutant Replicate B

description: see Strehlow et al. HMG 16:391 (2007)


title: Non-mutant Replicate C

description: see Strehlow et al. HMG 16:391 (2007)


title: litter 1, P14 V1 Litter 1C


title: Upland Cotton fiber Expression at 10dpa relative to 5dpa

city: Lubbock

first: Thea

middle: A

last: Wilkins

state: TX

address: 2500 Broadway,Campus Box 42122

department: Plant and Soil Sciences

institute: Texas Tech University

description: PDF files of detailed experimental protocols for RNA isolation (SOP MA002 v1.1), amino-allyl labeling (SOP MA003 v2.1) and microarray hybridization (SOP MA004 v2.1) can be accessed at Cotton Functional Genomics Center website.

hyb_protocol: Printed slides were pre-hybridized in a 50-ml solution of 5X SSC, 0.1% SDS, and 0.1 µg/µl BSA in a sealed coplin jar for 45 min @ 42ºC, followed by two washes of 10 sec each in filtered ddH2O, and dried with filtered compressed air. The final hybridization solution (50 µl) contained amino-labeled cDNA in 30% formamide, 5X SSC, 0.1% SDS, and 0.1 µg/µl sheared salmon sperm DNA and was applied to the slide surface using mSeries LifterSlips (Erie Scientific). After incubating at 42ºC for 16-20 hours in a humidified hybridization chamber (Genetix), the LifterSlips were removed by dipping slides in 2X SSC @ 42 °C. Slides were washed sequentially at 42ºC in 2X SSC, 0.2% SDS for 5 min, 0.5X SSC for 3 minutes, 4 times in 0.1X SSC for 1 minute per wash, and 0.05X SSC for 10 seconds, followed by a dip in ddH2O and drying with filtered compressed air.

scan_protocol: Hybridized slides were scanned using the  428 Array Scanner (Affymetrix) followed by feature extraction to quantify signal intensities using ImaGene 4.2 software (BioDiscovery).

data_processing: Microarray images were obtained using the 428 Array Scanner (Affymetrix) and signal intensities were quantified with ImaGene 4.2 (BioDiscovery). Low quality spots (dust particles, scratches, high background, or irregularly shaped spots) were manually flagged following visual inspection. Signal intensity was corrected based on blanks (N=274), and flagged spots with a background corrected intensity smaller than the average plus three standard deviations (>99.99% confidence interval) using a custom PERL script were excluded from further analysis. On average, 91.3% of all genes were present for analysis. Using the GNU statistical computing language R and LIMMA, linear models were applied to the data (Smyth, 2005). To remove any systematic intensity or space-dependent differences between Cy3 and Cy5 channels, data were normalized using a within-slide space-dependent global intensity (print-tip-lowess) normalization function provided in the R software package. The distribution of up and down regulated genes in data sets from hybridizations between distant developmental stages was not symmetrical as assumed for global normalization. To therefore analyze asymmetric results, reference calibration spots, which were spiked-in at a ratio of 1:1 in both channels, were weighted to 10 before initiating normalization procedures. Normalized data was fit to a linear model using the least squares method with an inter-duplicate correlation of 0.75 for duplicated spots. Results were interpreted using the 5 dpa time point as the common reference. The significance of differential expression between developmental stages was determined using the empirical Bayes method to shrink the gene-wise sample variances towards a common value. Resulting statistics were corrected for multiple-testing using Benjamini and Hochberg false discovery rates (Benjamini and Hochberg, 1995) and significant changes in gene expression were identified at p <0.05. Significance test was performed for each time point after 5 dpa relative to all preceding time points.

label: Alexa Fluor® 555 and Alexa Fluor® 647 (Dye Swap included)

organism: Gossypium hirsutum

source_name: Developing Cotton fiber at 10 days post anthesis (dpa)

label_protocol: Fluorescent-tagged amino-allyl labeled cDNA probes were generated by reverse transcription of cotton fiber total RNA (30 μg) spiked with reference mRNA spike mix (10, 50, 200, 400, 1000, and 2000 pg Alien Spike mRNAs 1 through 6, respectively, Stratagene), 5g poly-T21VQ primers (Operon), 0.2 mM each of dATP, dCTP, and dGTP (Sigma), and a 2:3 ratio of 0.2 mM aminoallyl-dUTP/dUTP mix (Sigma) in a total volume of 40 μl incubated at 42°C for 4 hours using SuperScript II (Invitrogen). Aminoallyl-labeled cDNA was purified using the QiaQuick PCR purification kit (Qiagen), and labeled with Cy3 or Cy5 monofunctional dyes (Amersham) according to manufacturer’s instructions. Labeled cDNA were quality controlled by measuring absorbance at 260, 280, 555, and 650. For each probe, the frequency of incorporation (FOI) of dye molecules expressed as the number of dye molecules per 1000 bps and concentration of cDNA were calculated and probes with an FOI < 20 were discarded.

growth_protocol: G. hirsutum L. cv. TM1, also known as upland, was grown in the green house under a 30/21°C day/night temperature regime in a randomized block design

extract_protocol: Total RNA was extracted using the modified hot borate method (Wan and Wilkins, 1994; Wilkins and Smart, 1996; Arpat et al., 2004)

tag: flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 10 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C.

source_name: Developing Cotton fiber at 5 days post anthesis (dpa)

tag: flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 5 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C.


title: Upland Cotton fiber Expression at 17dpa relative to 5dpa

source_name: Developing Cotton fiber at 17 days post anthesis (dpa)

tag: flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 17 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C.


title: Upland Cotton fiber Expression at 24 dpa relative to 5dpa

description: PDF files of detailed experimental protocols for RNA isolation (SOP MA002 v1.1), amino-allyl labeling (SOP MA003 v2.1) and microarray hybridization (SOP MA004 v2.1) can be accessed at Cotton Functional Genomics Center website

hyb_protocol: Printed slides were pre-hybridized in a 50-ml solution of 5X SSC, 0.1% SDS, and 0.1 µg/µl BSA in a sealed coplin jar for 45 min @ 42ºC, followed by two washes of 10 sec each in filtered ddH2O, and dried with filtered compressed air. The final hybridization solution (50 µl) contained amino-labeled cDNA in 30% formamide, 5X SSC, 0.1% SDS, and 0.1 µg/µl sheared salmon sperm DNA and was applied to the slide surface using mSeries LifterSlips (Erie Scientific). After incubating at 42ºC for 16-20 hours in a humidified hybridization chamber (Genetix), the LifterSlips were removed by dipping slides in 2X SSC @ 42 °C. Slides were washed sequentially at 42ºC in 2X SSC, 0.2% SDS for 5 min, 0.5X SSC for 3 minutes, 4 times in 0.1X SSC for 1 minute per wash, and 0.05X SSC for 10 seconds, followed by a dip in ddH2O and drying with filtered compressed air

scan_protocol: Hybridized slides were scanned using the 428 Array Scanner (Affymetrix) followed by feature extraction to quantify signal intensities using ImaGene 4.2 software (BioDiscovery).

source_name: Developing Cotton fiber at 24 days post anthesis (dpa)

label_protocol: Fluorescent-tagged amino-allyl labeled cDNA probes were generated by reverse transcription of cotton fiber total RNA (30 μg) spiked with reference mRNA spike mix (10, 50, 200, 400, 1000, and 2000 pg Alien Spike mRNAs 1 through 6, respectively, Stratagene), 5mg poly-T21VQ primers (Operon), 0.2 mM each of dATP, dCTP, and dGTP (Sigma), and a 2:3 ratio of 0.2 mM aminoallyl-dUTP/dUTP mix (Sigma) in a total volume of 40 μl incubated at 42°C for 4 hours using SuperScript II (Invitrogen). Aminoallyl-labeled cDNA was purified using the QiaQuick PCR purification kit (Qiagen), and labeled with Cy3 or Cy5 monofunctional dyes (Amersham) according to manufacturer’s instructions. Labeled cDNA were quality controlled by measuring absorbance at 260, 280, 555, and 650. For each probe, the frequency of incorporation (FOI) of dye molecules expressed as the number of dye molecules per 1000 bps and concentration of cDNA were calculated and probes with an FOI < 20 were discarded.

tag: flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 21 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C.


title: Pima S7 Cotton fiber Expression at 21dpa relative to 5dpa

hyb_protocol: The hybridization was performed according to Arpat et al., 2004. Printed slides were pre-hybridized in 5X SSC, 0.1% SDS, and 1 mg/µl BSA in a sealed coplin jar for 45 minutes at 42˚C, followed by two washes of 10 sec each in filtered ddH2O preheated to 42˚C, and dried with filtered compressed air. Alexa-labeled cDNA (500 ng/fluor or the equivalent of 40 to 45 pmol of dye depending upon the frequency of incorporation (FOI)) was suspended in 45µl of hybridization buffer (25% formamide, 4.16X SSC, 0.08% SDS, and 0.1 µg/µl sheared salmon sperm DNA) and loaded underneath the cover-slip (M Series LifterSlip, 22x60mm, Erie Scientific) using capillary action. Following hybridization at 42ºC for 16-18 hours in a humidified hybridization chamber (Genetix), slides were washed sequentially at 42ºC in 2X SSC, 0.2% SDS for 5 min, 0.5X SSC for 3 minutes, 4 times in 0.1X SSC for 1 minute per wash, and 0.05X SSC for 10 seconds, followed by drying with filtered compressed air.

scan_protocol: Hybridized slides were scanned using a GenPix3000 array scanner (Axon Instruments, CA, USA) followed by feature extraction to quantify signal intensities using ImaGene 4.2 software (BioDiscovery).

data_processing: Data were filtered and corrected for bias using the following steps: (1) Low quality spots (dust particles, scratches, high background, or irregularly shaped spots) were manually flagged and excluded. (2) Spot intensities were corrected by subtracting the mean of the background intensities from the signal intensity to reduce background noise. (3) Corrected spot intensities lower than the mean of corrected buffer spot plus 3 STDEV (Standard Deviation) were excluded (Hüser et al., 2003). (4) The absolute ratios (M) of dye swaps were correlated and the upper most 30% quartile of divergent data points were removed. This cut-off value enhanced the correlation between dye swaps by increasing the linearity. (5) Exclusion of all genes in which <60% of their data points did not pass all filtration steps. Reference calibration spots, which were spiked-in at a 1:1 ratio in both channels, were weighted to 10 before normalizing data. In order to adjust for effects that arise from variation inherent to microarray technology rather than biological differences in the RNA samples, filtered data was normalized using intensity-dependent normalization (Yang et al., 2002). The robust scatter plot smoother ‘Lowess’ implemented in R (version2.0.1) statistical software package and LIMMA (version 1.9.0) was used to perform a local per chip normalization. To make full use of within-array duplicated spots, LIMMA’s pooled correlation method (Symth et al., 2003) was used to estimate the strength of the correlation between duplicated spots by fitting separate linear models to the expression data for each gene, but with a common value for the between-replicate correlations. Normalized expression data at each time point was used as a reference point for all other time points (global reference) to calculate the relative expression, meaning that the expression at any given time point will be estimated independently six times relative to each of the other six time points.

organism: Gossypium barbadense

source_name: Developing Cotton fiber at 21 days post anthesis (dpa)

label_protocol:
Total RNA samples were reverse transcribed and fluorescently labeled using the amino-allyl reverse transcription labeling protocol (Hughes et al., 2001; Arpat et al., 2004).
Total RNA (10 μg) spiked with 1000 pg of a reference mRNA spike mix (Lucidea Universal Scorecard, Amersham Pharmacia) was used to synthesize first-strand cDNA in the presence of amino allyl-modified dUTP (aa-dUTP) (Arpat et al., 2004, Hughes et al., 2001). The reverse transcription reaction mix contained ~10 µg “spiked” total RNA, 5g poly-T21VQ primers (Operon), 0.2 mM dNTPs (Sigma), 0.2 mM aminoallyl-dUTP/dUTP (Sigma) in a 2:3 ratio, and 2.5 U SuperScript III (Invitrogen). Following incubation for 2 hours at 45°C, the aminoallyl-labeled cDNA was purified using Microcon YM-30 columns (MilliPore) according to manufacturer’s instructions. Aminoallyl-cDNA was labeled using Alexa Fluor 555 and 647 succinimidyl ester dyes according to manufacturer’s instructions (Molecular Probes, Inc.), and purified using the QiaQuick PCR purification kit (Qiagen).

growth_protocol: G. barbadense L. cv. Pima S7, also known as Egyptian cotton, was grown in the green house under a 30/21°C day/night temperature regime in a randomized block design

tag: Flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 5 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C.


title: Upland Cotton fiber Expression at 21 dpa relative to 5dpa


title: Upland Cotton fiber Expression at 8dpa relative to 5dpa

source_name: Developing Cotton fiber at 8 days post anthesis (dpa)

tag: flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 8 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C

tag: flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 5 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C


title: Pima S7 Cotton fiber Expression at 24dpa relative to 5dpa

tag: Flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 24 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C

tag: Flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 5 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C


title: Upland Cotton fiber Expression at 14dpa relative to 5dpa

source_name: Developing Cotton fiber at 14 days post anthesis (dpa)

tag: flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 14 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C.


title: 3M STZ 6

status: Public on Jun 11 2008

city: Hershey

first: Penn State

last: COM

address: 500 University Drive

department: Genome Sciences Facility

institute: Penn State College of Medicine

description: Retina, experimental sample for 3 month post streptozotocin injection experiment

hyb_protocol: Arrays were hybridized at 37C for 18h in a shaking incubator.

scan_protocol: Arrays were scanned with Axon GenePixPro 4000B (Molecular Devices, Axon Instruments, Union City, CA).

data_processing: Raw values represent the final number of the spot after background is subtracted out. Normalized values represent median global normalization method, i.e. raw intensity/median intensity of all spots on the array

label: Alexa-647 Streptavidin

source_name: Retina, 3 M STZ

label_protocol: Biotin-labeled cRNA was prepared by linear amplification of the Poly(A)+ RNA population within the total RNA sample

extract_protocol: Tri-Reagent/BCP ( Molecular Research Center, Cincinnati, OH ).  Cleanup with Qiagen ( Valencia, CA ) Rneasy final step

tag: Sprague Dawley, male, retina


title: 3M STZ 2


title: Pima S7 Cotton fiber Expression at 17dpa relative to 5dpa

tag: Flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 17 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C.


title: 3M STZ 5


title: 3M STZ 3


title: PimaS7 Cotton fiber Expression at 11dpa relative to 5dpa

source_name: Developing Cotton fiber at 11 days post anthesis (dpa)

tag: flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 11 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C.


title: 3M STZ 4


title: PimaS7 Cotton fiber Expression at 8dpa relative to 5dpa

tag: Flowers were tagged on the day of anthesis (0 days post anthesis (dpa)). Developing bolls from the first fruiting positions closest to the stem were collected at 8 dpa between 8 a.m. and 10 a.m. to eliminate diurnal effects. Bolls were collected from different plants, and immediately mingled, frozen in liquid Nitrogen, and then stored in 50-ml polypropylene tubes at -80°C.


title: 3M Control 2

description: Retina, control sample for 3 month post streptozotocin injection experiment

source_name: Retina, 3 M Control


title: 3M STZ 1


title: 3M Control 6


title: 3M Control 5


title: 3M Control 4


title: 3M Control 3


title: 3M Control 1


title: 1M Control 4

description: Retina, control sample for 1 month post streptozotocin injection experiment

source_name: Retina, 1 M Control


title: 1M STZ 3

description: Retina, experimental sample for 1 month post streptozotocin injection experiment

source_name: Retina, 1 M STZ


title: 1M STZ 6


title: 1M Control 6


title: 1M STZ 2


title: 1M STZ 5


title: 1M Control 1

source_name: Retina, 1 M control


title: 1M Control 3


title: 1M STZ 1


title: Distinctive molecular signature of membrane type-1 matrix metalloproteinase (MT1-MMP) in cancer: HT-siRNA rep2

city: La Jolla

first: Roy

middle: M

last: Williams

address: 3030 Science Park Road

department: Regenerative Medicine

institute: The Scripps Research Institute

description: HT-siRNA rep 2: 2nd biological replicate of 2.

hyb_protocol: As described in the illumina human ref8 hybridisation protocol. Doc#11176837 Rev E.

scan_protocol: As suggested by Illumina using the illumina scanner

data_processing: none: raw data from Beadstudio

label: Streptavidin Cy3

source_name: ATCC; in house cell culture

label_protocol: As described in the illumina human Ref8 chip processing protocol. Briefly generation of biotin labelled cRNA from the product of RT cDNA synthesis and 2nd strand cDNA synthesis.

growth_protocol: HT and U cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (DMEM/FCS) and 10 μg/ml gentamicin.

extract_protocol: Illumina total prep RNA amplification kit (Ambion catalog#IL1791)

treatment_protocol: HT cells were stably transfected with the wild type MT1-MMP, MT1-MMP siRNA and scrambled siRNA using LipofectAMINE (Invitrogen) to generate HT-MT, HT-siRNA and HTsiRNAscr cells, respectively.

tag: Transfected HT0810 cell line


title: Distinctive molecular signature of membrane type-1 matrix metalloproteinase (MT1-MMP) in cancer: HT_siRNA rep1

description: HT_siRNA rep1: 1st biological replicate of 2.

tag: The parental human fibrosarcoma HT1080 (HT cells) were obtained from ATCC


title: Distinctive molecular signature of membrane type-1 matrix metalloproteinase (MT1-MMP) in cancer: HT-MT1 rep2

description: HT rep 2: 2nd biological replicate of 2.

tag: Transfected cell line HT0810


title: Patient 156 Core Set (custom panel)

status: Public on Jun 10 2008

city: Rochester

first: Robert

middle: B.

last: Jenkins

state: MN

address: 200 First Street SW

department: Laboratory Medicine and Pathology

institute: Mayo Clinic

hyb_protocol: hybridization was performed in accordance with the manufacturer's instructions

scan_protocol: Arrays were scanned using Illumina's BeadArray Reader

data_processing: Illumina's Bead Studio Software using no normalization was used to process the image files. The raw data was then normalized using cyclic loess (fastlo). The normalized value for the probes was averaged to determine the expression level for the gene. The DASL method labels each sample with a mixture of CY3 and Cy5. Only a single sample is applied to each array.  The scanner measures fluorescence of both Cy3 and Cy5.  This data is contained in the red and grn files for each sample. The bead studio software averages the red and green signals to provide a single value for the expression of a particular probe.

label: cy3, cy5

source_name: primary prostate cancer

label_protocol: cy3, cy5 labeling was performed in accordance with the manufacturer's instructions

extract_protocol: Four freshly cut 10 micron sections of FFPE tissue were deparaffinized and the Gleason dominant cancer focus was macrodissected. RNA was extracted using the High Pure RNA Paraffin Kit from Roche (Indianapolis, IN).

tag: Case-Control Group

value: Systemic

tag: Training or Validation

value: trn

tag: Age (yrs) at RRP

tag: PSA (ng/ml) at RRP

tag: Revised Gleason Score

tag: Stage

tag: Ploidy

value: tetraploid

tag: First Rising PSA (ng/ml)

tag: Time (yrs) from RRP to first rising PSA

tag: Second Rising PSA (ng/ml)

tag: Time (yrs) from RRP to second rising PSA

tag: PSA Slope (ng/ml/yr)

tag: Time (yrs) from PSA recurrence to systemic disease

tag: Years of Followup after RRP

tag: patient's status

value: Alive

tag: Prostate cancer specific death

value: No


title: 1M Control 2

tag: Sprague Dawley, male, retina


title: 1M Control 5


title: Patient 007 Core Set (custom panel)

tag: Case-Control Group

value: PSA

value: val

value: diploid


title: Patient 270 Core Set (custom panel)

tag: Training or Validation

value: TxN+

value: Deceased

value: Yes


title: 1M STZ 4


title: Patient 626 Core Set (custom panel)

tag: Age (yrs) at RRP


title: Patient 452 Core Set (custom panel)

tag: PSA (ng/ml) at RRP


title: No.5

source_name: REF

tag: RNA from cells grown from 0.5 million/ml for 48hr. without ecdysone treatment

source_name: EXP

tag: RNA from cells grown from 0.5 million/ml for 48hr. and then under ecdysone (0.5uM) 1hr


title: Distinctive molecular signature of membrane type-1 matrix metalloproteinase (MT1-MMP) in cancer: HT-MT1_rep1

description: 1st biological replicate of 2.

source_name: cell line HT1080 (HT cells)

tag: The parental human fibrosarcoma HT1080 (HT cells) were obtained from ATCC


title: Distinctive molecular signature of membrane type-1 matrix metalloproteinase (MT1-MMP) in cancer HT rep 2

tag: Transfected cell culture. HT rep 2.


title: Distinctive molecular signature of membrane type-1 matrix metalloproteinase (MT1-MMP) in cancer

description: 1st biological replicate of 2.

tag: The parental human fibrosarcoma HT1080 (HT cells) and human glioma U251 (U cells) were obtained from ATCC (Rockville, MD). HT and U cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (DMEM/FCS) and 10 μg/ml gentamicin.


title: Patient 480 Core Set (custom panel)

tag: Revised Gleason Score

tag: Stage

tag: Ploidy

value: aneuploid

tag: First Rising PSA (ng/ml)

tag: Time (yrs) from RRP to first rising PSA

tag: Second Rising PSA (ng/ml)


title: Patient 599 Core Set (custom panel)

value: NED

tag: Time (yrs) from RRP to second rising PSA

tag: PSA Slope (ng/ml/yr)

tag: Time (yrs) from PSA recurrence to systemic disease

tag: Years of Followup after RRP

tag: patient's status

tag: Prostate cancer specific death


title: Patient 256 Core Set (custom panel)

tag: Case-Control Group

tag: Training or Validation

tag: Age (yrs) at RRP

tag: PSA (ng/ml) at RRP


title: Patient 129 Core Set (custom panel)


title: Patient 603 Core Set (custom panel)


title: Patient 362 Core Set (custom panel)


title: Patient 265 Core Set (custom panel)


title: Patient 429 Core Set (custom panel)


title: Patient 436 Core Set (custom panel)


title: Patient 125 Core Set (custom panel)


title: Patient 251 Core Set (custom panel)


title: Patient 099 Core Set (custom panel)


title: Patient 223 Core Set (custom panel)


title: Patient 079 Core Set (custom panel)


title: Patient 189 Core Set (custom panel)


title: Patient 109 Core Set (custom panel)


title: Patient 573 Core Set (custom panel)


title: Patient 093 Core Set (custom panel)


title: Patient 560 Core Set (custom panel)


title: Patient 344 Core Set (custom panel)


title: Patient 517 Core Set (custom panel)


title: Patient 286 Core Set (custom panel)


title: Patient 090 Core Set (custom panel)


title: Patient 632 Core Set (cancer panel)


title: Patient 630 Core Set (cancer panel)


title: Patient 635 Core Set (cancer panel)


title: Patient 633 Core Set (cancer panel)


title: Patient 639 Core Set (cancer panel)


title: Patient 634 Core Set (cancer panel)


title: Patient 638 Core Set (cancer panel)


title: Patient 637 Core Set (cancer panel)


title: Patient 526 Core Set (custom panel)


title: Patient 185 Core Set (custom panel)


title: Patient 505 Core Set (custom panel)


title: Patient 629 Core Set (cancer panel)


title: Patient 310 Core Set (custom panel)


title: Patient 627 Core Set (custom panel)


title: Patient 619 Core Set (custom panel)


title: Patient 627 Core Set (cancer panel)


title: Patient 611 Core Set (custom panel)


title: Patient 628 Core Set (cancer panel)


title: Patient 634 Core Set (custom panel)


title: Patient 625 Core Set (cancer panel)


title: Patient 624 Core Set (cancer panel)


title: Patient 621 Core Set (cancer panel)


title: Patient 586 Core Set (custom panel)


title: Patient 622 Core Set (cancer panel)


title: Patient 633 Core Set (custom panel)


title: Patient 594 Core Set (custom panel)


title: Patient 620 Core Set (cancer panel)


title: Patient 623 Core Set (cancer panel)


title: Patient 618 Core Set (cancer panel)


title: Patient 562 Core Set (custom panel)


title: Patient 602 Core Set (custom panel)


title: Patient 610 Core Set (custom panel)


title: Patient 616 Core Set (cancer panel)


title: Patient 619 Core Set (cancer panel)


title: Patient 615 Core Set (cancer panel)


title: Patient 618 Core Set (custom panel)


title: Patient 617 Core Set (cancer panel)


title: Patient 593 Core Set (custom panel)


title: Patient 601 Core Set (custom panel)


title: Patient 584 Core Set (custom panel)


title: Patient 577 Core Set (custom panel)


title: Patient 614 Core Set (cancer panel)


title: Patient 576 Core Set (custom panel)


title: Patient 636 Core Set (cancer panel)


title: Patient 568 Core Set (custom panel)


title: Patient 612 Core Set (cancer panel)


title: Patient 610 Core Set (cancer panel)


title: Patient 613 Core Set (cancer panel)


title: Patient 625 Core Set (custom panel)


title: Patient 127 Core Set (custom panel)


title: Patient 607 Core Set (cancer panel)


title: Patient 600 Core Set (custom panel)


title: Patient 639 Core Set (custom panel)


title: Patient 632 Core Set (custom panel)


title: Patient 602 Core Set (cancer panel)


title: Patient 606 Core Set (cancer panel)


title: Patient 609 Core Set (custom panel)


title: Patient 592 Core Set (custom panel)


title: Patient 605 Core Set (cancer panel)


title: Patient 609 Core Set (cancer panel)


title: Patient 603 Core Set (cancer panel)


title: Patient 583 Core Set (custom panel)


title: Patient 575 Core Set (custom panel)


title: Patient 604 Core Set (cancer panel)


title: Patient 601 Core Set (cancer panel)


title: Patient 617 Core Set (custom panel)


title: Patient 600 Core Set (cancer panel)


title: Patient 567 Core Set (custom panel)


title: Patient 626 Core Set (cancer panel)


title: Patient 599 Core Set (cancer panel)


title: Patient 119 Core Set (custom panel)


title: Patient 559 Core Set (custom panel)


title: Patient 591 Core Set (custom panel)


title: Patient 598 Core Set (cancer panel)


title: Patient 574 Core Set (custom panel)


title: Patient 582 Core Set (custom panel)


title: Patient 638 Core Set (custom panel)


title: Patient 596 Core Set (cancer panel)


title: Patient 592 Core Set (cancer panel)


title: Patient 616 Core Set (custom panel)


title: Patient 624 Core Set (custom panel)


title: Patient 607 Core Set (custom panel)


title: Patient 593 Core Set (cancer panel)


title: Patient 566 Core Set (custom panel)


title: Patient 594 Core Set (cancer panel)


title: Patient 595 Core Set (cancer panel)


title: Patient 588 Core Set (cancer panel)


title: Patient 558 Core Set (custom panel)


title: Patient 591 Core Set (cancer panel)


title: Patient 597 Core Set (cancer panel)


title: Patient 590 Core Set (cancer panel)


title: Patient 630 Core Set (custom panel)


title: Patient 587 Core Set (cancer panel)


title: Patient 623 Core Set (custom panel)


title: Patient 615 Core Set (custom panel)


title: Patient 584 Core Set (cancer panel)


title: Patient 606 Core Set (custom panel)


title: Patient 611 Core Set (cancer panel)


title: Patient 565 Core Set (custom panel)


title: Patient 590 Core Set (custom panel)


title: Patient 581 Core Set (cancer panel)


title: Patient 557 Core Set (custom panel)


title: Patient 577 Core Set (cancer panel)


title: Patient 576 Core Set (cancer panel)


title: Patient 578 Core Set (cancer panel)


title: Patient 629 Core Set (custom panel)


title: Patient 580 Core Set (cancer panel)


title: Patient 637 Core Set (custom panel)


title: Patient 614 Core Set (custom panel)


title: Patient 622 Core Set (custom panel)


title: Patient 582 Core Set (cancer panel)


title: Patient 581 Core Set (custom panel)


title: Patient 583 Core Set (cancer panel)


title: Patient 573 Core Set (cancer panel)


title: Patient 598 Core Set (custom panel)


title: Patient 597 Core Set (custom panel)


title: Patient 605 Core Set (custom panel)


title: Patient 579 Core Set (cancer panel)


title: Patient 586 Core Set (cancer panel)


title: Patient 572 Core Set (cancer panel)


title: Patient 574 Core Set (cancer panel)


title: Patient 580 Core Set (custom panel)


title: Patient 575 Core Set (cancer panel)


title: Patient 564 Core Set (custom panel)


title: Patient 568 Core Set (cancer panel)


title: Patient 556 Core Set (custom panel)


title: Patient 571 Core Set (cancer panel)


title: Patient 572 Core Set (custom panel)


title: Patient 570 Core Set (cancer panel)


title: Patient 636 Core Set (custom panel)


title: Patient 628 Core Set (custom panel)


title: Patient 596 Core Set (custom panel)


title: Patient 564 Core Set (cancer panel)


title: Patient 558 Core Set (cancer panel)


title: Patient 565 Core Set (cancer panel)


title: Patient 559 Core Set (cancer panel)


title: Patient 562 Core Set (cancer panel)


title: Patient 563 Core Set (cancer panel)


title: Patient 560 Core Set (cancer panel)


title: Patient 621 Core Set (custom panel)


title: Patient 566 Core Set (cancer panel)


title: Patient 571 Core Set (custom panel)


title: Patient 563 Core Set (custom panel)


title: Patient 604 Core Set (custom panel)


title: Patient 567 Core Set (cancer panel)


title: Patient 579 Core Set (custom panel)


title: Patient 555 Core Set (custom panel)


title: Patient 588 Core Set (custom panel)


title: Patient 613 Core Set (custom panel)


title: Patient 553 Core Set (cancer panel)


title: Patient 555 Core Set (cancer panel)


title: Patient 556 Core Set (cancer panel)


title: Patient 557 Core Set (cancer panel)


title: Patient 620 Core Set (custom panel)


title: Patient 554 Core Set (cancer panel)


title: Patient 635 Core Set (custom panel)


title: Patient 612 Core Set (custom panel)


title: Patient 570 Core Set (custom panel)


title: Patient 587 Core Set (custom panel)


title: Patient 578 Core Set (custom panel)


title: Patient 552 Core Set (cancer panel)


title: Patient 595 Core Set (custom panel)


title: Patient 551 Core Set (cancer panel)


title: Patient 550 Core Set (cancer panel)


title: Patient 549 Core Set (cancer panel)


title: Patient 547 Core Set (custom panel)


title: Patient 547 Core Set (cancer panel)


title: Patient 548 Core Set (cancer panel)


title: Patient 554 Core Set (custom panel)


title: Patient 544 Core Set (cancer panel)


title: Patient 179 Core Set (custom panel)


title: Patient 531 Core Set (custom panel)


title: Patient 543 Core Set (cancer panel)


title: Patient 545 Core Set (cancer panel)


title: Patient 523 Core Set (custom panel)


title: Patient 542 Core Set (cancer panel)


title: Patient 541 Core Set (cancer panel)


title: Patient 546 Core Set (cancer panel)


title: Patient 540 Core Set (custom panel)


title: Patient 540 Core Set (cancer panel)


title: Patient 499 Core Set (custom panel)


title: Patient 537 Core Set (cancer panel)


title: Patient 536 Core Set (cancer panel)


title: Patient 515 Core Set (custom panel)


title: Patient 507 Core Set (custom panel)


title: Patient 482 Core Set (custom panel)


title: Patient 539 Core Set (cancer panel)


title: Patient 534 Core Set (cancer panel)


title: Patient 531 Core Set (cancer panel)


title: Patient 533 Core Set (cancer panel)


title: Patient 538 Core Set (cancer panel)


title: Patient 530 Core Set (cancer panel)


title: Patient 539 Core Set (custom panel)


title: Patient 522 Core Set (custom panel)


title: Patient 530 Core Set (custom panel)


title: Patient 546 Core Set (custom panel)


title: Patient 506 Core Set (custom panel)


title: Patient 528 Core Set (cancer panel)


title: Patient 468 Core Set (custom panel)


title: Patient 498 Core Set (custom panel)


title: Patient 491 Core Set (custom panel)


title: Patient 490 Core Set (custom panel)


title: Patient 514 Core Set (custom panel)


title: Patient 526 Core Set (cancer panel)


title: Patient 529 Core Set (cancer panel)


title: Patient 527 Core Set (cancer panel)


title: Patient 475 Core Set (custom panel)


title: Patient 524 Core Set (cancer panel)


title: Patient 545 Core Set (custom panel)


title: Patient 523 Core Set (cancer panel)


title: Patient 522 Core Set (cancer panel)


title: Patient 529 Core Set (custom panel)


title: Patient 521 Core Set (cancer panel)


title: Patient 521 Core Set (custom panel)


title: Patient 553 Core Set (custom panel)


title: Patient 517 Core Set (cancer panel)


title: Patient 520 Core Set (cancer panel)


title: Patient 518 Core Set (cancer panel)


title: Patient 519 Core Set (cancer panel)


title: Patient 525 Core Set (cancer panel)


title: Patient 481 Core Set (custom panel)


title: Patient 489 Core Set (custom panel)


title: Patient 538 Core Set (custom panel)


title: Patient 497 Core Set (custom panel)


title: Patient 474 Core Set (custom panel)


title: Patient 112 Core Set (custom panel)


title: Patient 514 Core Set (cancer panel)


title: Patient 515 Core Set (cancer panel)


title: Patient 552 Core Set (custom panel)


title: Patient 513 Core Set (cancer panel)


title: Patient 537 Core Set (custom panel)


title: Patient 509 Core Set (cancer panel)


title: Patient 512 Core Set (cancer panel)


title: Patient 544 Core Set (custom panel)


title: Patient 511 Core Set (cancer panel)


title: Patient 512 Core Set (custom panel)


title: Patient 516 Core Set (cancer panel)


title: Patient 510 Core Set (cancer panel)


title: Patient 528 Core Set (custom panel)


title: Patient 520 Core Set (custom panel)


title: Patient 496 Core Set (custom panel)


title: Patient 508 Core Set (cancer panel)


title: Patient 504 Core Set (custom panel)


title: Patient 507 Core Set (cancer panel)


title: Patient 488 Core Set (custom panel)


title: Patient 505 Core Set (cancer panel)


title: Patient 504 Core Set (cancer panel)


title: Patient 506 Core Set (cancer panel)


title: Patient 479 Core Set (custom panel)


title: Patient 513 Core Set (custom panel)


title: Patient 473 Core Set (custom panel)


title: Patient 100 Core Set (custom panel)


title: Patient 551 Core Set (custom panel)


title: Patient 500 Core Set (cancer panel)


title: Patient 503 Core Set (cancer panel)


title: Patient 501 Core Set (cancer panel)


title: Patient 543 Core Set (custom panel)


title: Patient 536 Core Set (custom panel)


title: Patient 527 Core Set (custom panel)


title: Patient 495 Core Set (cancer panel)


title: Patient 499 Core Set (cancer panel)


title: Patient 519 Core Set (custom panel)


title: Patient 496 Core Set (cancer panel)


title: Patient 493 Core Set (cancer panel)


title: Patient 494 Core Set (cancer panel)


title: Patient 511 Core Set (custom panel)


title: Patient 495 Core Set (custom panel)


title: Patient 503 Core Set (custom panel)


title: Patient 486 Core Set (custom panel)


title: Patient 478 Core Set (custom panel)


title: Patient 498 Core Set (cancer panel)


title: Patient 497 Core Set (cancer panel)


title: Patient 489 Core Set (cancer panel)


title: Patient 491 Core Set (cancer panel)


title: Patient 490 Core Set (cancer panel)


title: Patient 518 Core Set (custom panel)


title: Patient 510 Core Set (custom panel)


title: Patient 542 Core Set (custom panel)


title: Patient 488 Core Set (cancer panel)


title: Patient 472 Core Set (custom panel)


title: Patient 494 Core Set (custom panel)


title: Patient 483 Core Set (cancer panel)


title: Patient 486 Core Set (cancer panel)


title: Patient 485 Core Set (cancer panel)


title: Patient 534 Core Set (custom panel)


title: Patient 481 Core Set (cancer panel)


title: Patient 484 Core Set (cancer panel)


title: Patient 485 Core Set (custom panel)


title: Patient 550 Core Set (custom panel)


title: Patient 477 Core Set (custom panel)


title: Patient 467 Core Set (custom panel)


title: Patient 471 Core Set (custom panel)


title: Patient 479 Core Set (cancer panel)


title: Patient 480 Core Set (cancer panel)


title: Patient 541 Core Set (custom panel)


title: Patient 097 Core Set (custom panel)


title: Patient 549 Core Set (custom panel)


title: Patient 476 Core Set (cancer panel)


title: Patient 477 Core Set (cancer panel)


title: Patient 533 Core Set (custom panel)


title: Patient 492 Core Set (cancer panel)


title: Patient 478 Core Set (cancer panel)


title: Patient 475 Core Set (cancer panel)


title: Patient 525 Core Set (custom panel)


title: Patient 473 Core Set (cancer panel)


title: Patient 493 Core Set (custom panel)


title: Patient 472 Core Set (cancer panel)


title: Patient 471 Core Set (cancer panel)


title: Patient 474 Core Set (cancer panel)


title: Patient 501 Core Set (custom panel)


title: Patient 509 Core Set (custom panel)


title: Patient 470 Core Set (cancer panel)


title: Patient 476 Core Set (custom panel)


title: Patient 470 Core Set (custom panel)


title: Patient 467 Core Set (cancer panel)


title: Patient 484 Core Set (custom panel)


title: Patient 468 Core Set (cancer panel)


title: Patient 524 Core Set (custom panel)


title: Patient 482 Core Set (cancer panel)


title: Patient 548 Core Set (custom panel)


title: Patient 516 Core Set (custom panel)


title: Patient 466 Core Set (cancer panel)


title: Patient 465 Core Set (cancer panel)


title: Patient 469 Core Set (cancer panel)


title: Patient 464 Core Set (cancer panel)


title: Patient 463 Core Set (cancer panel)


title: Patient 508 Core Set (custom panel)


title: Patient 500 Core Set (custom panel)


title: Patient 462 Core Set (cancer panel)


title: Patient 483 Core Set (custom panel)


title: Patient 461 Core Set (cancer panel)


title: Patient 492 Core Set (custom panel)


title: Patient 459 Core Set (cancer panel)


title: Patient 460 Core Set (cancer panel)


title: Patient 469 Core Set (custom panel)


title: Patient 466 Core Set (custom panel)


title: Patient 459 Core Set (custom panel)


title: Patient 418 Core Set (custom panel)


title: Patient 457 Core Set (cancer panel)


title: Patient 444 Core Set (custom panel)


title: Patient 426 Core Set (custom panel)


title: Patient 456 Core Set (cancer panel)


title: Patient 455 Core Set (cancer panel)


title: Patient 458 Core Set (cancer panel)


title: Patient 452 Core Set (cancer panel)


title: Patient 453 Core Set (cancer panel)


title: Patient 402 Core Set (custom panel)


title: Patient 410 Core Set (custom panel)


title: Patient 454 Core Set (cancer panel)


title: Patient 394 Core Set (custom panel)


title: Patient 465 Core Set (custom panel)


title: Patient 386 Core Set (custom panel)


title: Patient 450 Core Set (cancer panel)


title: Patient 379 Core Set (custom panel)


title: Patient 451 Core Set (cancer panel)


title: Patient 449 Core Set (cancer panel)


title: Patient 458 Core Set (custom panel)


title: Patient 448 Core Set (cancer panel)


title: Patient 446 Core Set (cancer panel)


title: Patient 447 Core Set (cancer panel)


title: Patient 451 Core Set (custom panel)


title: Patient 445 Core Set (cancer panel)


title: Patient 434 Core Set (custom panel)


title: Patient 425 Core Set (custom panel)


title: Patient 417 Core Set (custom panel)


title: Patient 442 Core Set (cancer panel)


title: Patient 401 Core Set (custom panel)


title: Patient 443 Core Set (cancer panel)


title: Patient 444 Core Set (cancer panel)


title: Patient 409 Core Set (custom panel)


title: Patient 443 Core Set (custom panel)


title: Patient 441 Core Set (cancer panel)


title: Patient 439 Core Set (cancer panel)


title: Patient 385 Core Set (custom panel)


title: Patient 438 Core Set (cancer panel)


title: Patient 393 Core Set (custom panel)


title: Patient 075 Core Set (custom panel)


title: Patient 464 Core Set (custom panel)


title: Patient 436 Core Set (cancer panel)


title: Patient 433 Core Set (cancer panel)


title: Patient 442 Core Set (custom panel)


title: Patient 434 Core Set (cancer panel)


title: Patient 424 Core Set (custom panel)


title: Patient 450 Core Set (custom panel)


title: Patient 433 Core Set (custom panel)


title: Patient 416 Core Set (custom panel)


title: Patient 430 Core Set (cancer panel)


title: Patient 427 Core Set (cancer panel)


title: Patient 426 Core Set (cancer panel)


title: Patient 400 Core Set (custom panel)


title: Patient 429 Core Set (cancer panel)


title: Patient 457 Core Set (custom panel)


title: Patient 425 Core Set (cancer panel)


title: Patient 392 Core Set (custom panel)


title: Patient 423 Core Set (cancer panel)


title: Patient 408 Core Set (custom panel)


title: Patient 384 Core Set (custom panel)


title: Patient 456 Core Set (custom panel)


title: Patient 424 Core Set (cancer panel)


title: Patient 421 Core Set (cancer panel)


title: Patient 422 Core Set (cancer panel)


title: Patient 432 Core Set (cancer panel)


title: Patient 463 Core Set (custom panel)


title: Patient 449 Core Set (custom panel)


title: Patient 419 Core Set (cancer panel)


title: Patient 441 Core Set (custom panel)


title: Patient 417 Core Set (cancer panel)


title: Patient 415 Core Set (custom panel)


title: Patient 414 Core Set (cancer panel)


title: Patient 399 Core Set (custom panel)


title: Patient 060 Core Set (custom panel)


title: Patient 420 Core Set (cancer panel)


title: Patient 432 Core Set (custom panel)


title: Patient 383 Core Set (custom panel)


title: Patient 415 Core Set (cancer panel)


title: Patient 418 Core Set (cancer panel)


title: Patient 413 Core Set (cancer panel)


title: Patient 412 Core Set (cancer panel)


title: Patient 455 Core Set (custom panel)


title: Patient 462 Core Set (custom panel)


title: Patient 430 Core Set (custom panel)


title: Patient 408 Core Set (cancer panel)


title: Patient 416 Core Set (cancer panel)


title: Patient 423 Core Set (custom panel)


title: Patient 410 Core Set (cancer panel)


title: Patient 409 Core Set (cancer panel)


title: Patient 407 Core Set (cancer panel)


title: Patient 407 Core Set (custom panel)


title: Patient 422 Core Set (custom panel)


title: Patient 404 Core Set (cancer panel)


title: Patient 398 Core Set (custom panel)


title: Patient 411 Core Set (cancer panel)


title: Patient 414 Core Set (custom panel)


title: Patient 405 Core Set (cancer panel)


title: Patient 406 Core Set (custom panel)


title: Patient 040 Core Set (custom panel)


title: Patient 406 Core Set (cancer panel)


title: Patient 400 Core Set (cancer panel)


title: Patient 461 Core Set (custom panel)


title: Patient 403 Core Set (cancer panel)


title: Patient 397 Core Set (cancer panel)


title: Patient 402 Core Set (cancer panel)


title: Patient 401 Core Set (cancer panel)


title: Patient 447 Core Set (custom panel)


title: Patient 399 Core Set (cancer panel)


title: Patient 413 Core Set (custom panel)


title: Patient 454 Core Set (custom panel)


title: Patient 398 Core Set (cancer panel)


title: Patient 439 Core Set (custom panel)


title: Patient 448 Core Set (custom panel)


title: Patient 394 Core Set (cancer panel)


title: Patient 390 Core Set (custom panel)


title: Patient 421 Core Set (custom panel)


title: Patient 393 Core Set (cancer panel)


title: Patient 382 Core Set (custom panel)


title: Patient 396 Core Set (cancer panel)


title: Patient 397 Core Set (custom panel)


title: Patient 460 Core Set (custom panel)


title: Patient 395 Core Set (cancer panel)


title: Patient 405 Core Set (custom panel)


title: Patient 389 Core Set (custom panel)


title: Patient 390 Core Set (cancer panel)


title: Patient 446 Core Set (custom panel)


title: Patient 420 Core Set (custom panel)


title: Patient 392 Core Set (cancer panel)


title: Patient 412 Core Set (custom panel)


title: Patient 388 Core Set (cancer panel)


title: Patient 387 Core Set (cancer panel)


title: Patient 386 Core Set (cancer panel)


title: Patient 389 Core Set (cancer panel)


title: Patient 385 Core Set (cancer panel)


title: Patient 438 Core Set (custom panel)


title: Patient 381 Core Set (custom panel)


title: Patient 388 Core Set (custom panel)


title: Patient 383 Core Set (cancer panel)


title: Patient 453 Core Set (custom panel)


title: Patient 396 Core Set (custom panel)


title: Patient 382 Core Set (cancer panel)


title: Patient 404 Core Set (custom panel)


title: Patient 381 Core Set (cancer panel)


title: Patient 437 Core Set (custom panel)


title: Patient 445 Core Set (custom panel)


title: Patient 379 Core Set (cancer panel)


title: Patient 380 Core Set (cancer panel)


title: Patient 427 Core Set (custom panel)


title: Patient 384 Core Set (cancer panel)


title: Patient 378 Core Set (cancer panel)


title: Patient 403 Core Set (custom panel)


title: Patient 411 Core Set (custom panel)


title: Patient 375 Core Set (cancer panel)


title: Patient 376 Core Set (cancer panel)


title: Patient 374 Core Set (cancer panel)


title: Patient 373 Core Set (cancer panel)


title: Patient 372 Core Set (cancer panel)


title: Patient 387 Core Set (custom panel)


title: Patient 370 Core Set (cancer panel)


title: Patient 419 Core Set (custom panel)


title: Patient 373 Core Set (custom panel)


title: Patient 369 Core Set (cancer panel)


title: Patient 359 Core Set (custom panel)


title: Patient 343 Core Set (custom panel)


title: Patient 368 Core Set (cancer panel)


title: Patient 334 Core Set (custom panel)


title: Patient 326 Core Set (custom panel)


title: Patient 371 Core Set (cancer panel)


title: Patient 365 Core Set (cancer panel)


title: Patient 318 Core Set (custom panel)


title: Patient 395 Core Set (custom panel)


title: Patient 293 Core Set (custom panel)


title: Patient 364 Core Set (cancer panel)


title: Patient 363 Core Set (cancer panel)


title: Patient 378 Core Set (custom panel)


title: Patient 366 Core Set (custom panel)


title: Patient 362 Core Set (cancer panel)


title: Patient 360 Core Set (cancer panel)


title: Patient 361 Core Set (cancer panel)


title: Patient 358 Core Set (custom panel)


title: Patient 350 Core Set (custom panel)


title: Patient 366 Core Set (cancer panel)


title: Patient 359 Core Set (cancer panel)


title: Patient 342 Core Set (custom panel)


title: Patient 325 Core Set (custom panel)


title: Patient 357 Core Set (cancer panel)


title: Patient 358 Core Set (cancer panel)


title: Patient 355 Core Set (cancer panel)


title: Patient 308 Core Set (custom panel)


title: Patient 300 Core Set (custom panel)


title: Patient 317 Core Set (custom panel)


title: Patient 353 Core Set (cancer panel)


title: Patient 292 Core Set (custom panel)


title: Patient 354 Core Set (cancer panel)


title: Patient 365 Core Set (custom panel)


title: Patient 352 Core Set (cancer panel)


title: Patient 350 Core Set (cancer panel)


title: Patient 349 Core Set (cancer panel)


title: Patient 357 Core Set (custom panel)


title: Patient 356 Core Set (cancer panel)


title: Patient 347 Core Set (cancer panel)


title: Patient 348 Core Set (cancer panel)


title: Patient 349 Core Set (custom panel)


title: Patient 346 Core Set (cancer panel)


title: Patient 372 Core Set (custom panel)


title: Patient 341 Core Set (custom panel)


title: Patient 332 Core Set (custom panel)


title: Patient 324 Core Set (custom panel)


title: Patient 345 Core Set (cancer panel)


title: Patient 316 Core Set (custom panel)


title: Patient 344 Core Set (cancer panel)


title: Patient 034 Core Set (custom panel)


title: Patient 343 Core Set (cancer panel)


title: Patient 299 Core Set (custom panel)


title: Patient 376 Core Set (custom panel)


title: Patient 380 Core Set (custom panel)


title: Patient 342 Core Set (cancer panel)


title: Patient 341 Core Set (cancer panel)


title: Patient 371 Core Set (custom panel)


title: Patient 339 Core Set (cancer panel)


title: Patient 338 Core Set (cancer panel)


title: Patient 356 Core Set (custom panel)


title: Patient 336 Core Set (cancer panel)


title: Patient 337 Core Set (cancer panel)


title: Patient 323 Core Set (custom panel)


title: Patient 335 Core Set (cancer panel)


title: Patient 348 Core Set (custom panel)


title: Patient 334 Core Set (cancer panel)


title: Patient 339 Core Set (custom panel)


title: Patient 331 Core Set (custom panel)


title: Patient 332 Core Set (cancer panel)


title: Patient 331 Core Set (cancer panel)


title: Patient 315 Core Set (custom panel)


title: Patient 306 Core Set (custom panel)


title: Patient 364 Core Set (custom panel)


title: Patient 330 Core Set (cancer panel)


title: Patient 329 Core Set (cancer panel)


title: Patient 028 Core Set (custom panel)


title: Patient 327 Core Set (cancer panel)


title: Patient 375 Core Set (custom panel)


title: Patient 326 Core Set (cancer panel)


title: Patient 370 Core Set (custom panel)


title: Patient 298 Core Set (custom panel)


title: Patient 363 Core Set (custom panel)


title: Patient 355 Core Set (custom panel)


title: Patient 325 Core Set (cancer panel)


title: Patient 322 Core Set (cancer panel)


title: Patient 323 Core Set (cancer panel)


title: Patient 321 Core Set (cancer panel)


title: Patient 347 Core Set (custom panel)


title: Patient 324 Core Set (cancer panel)


title: Patient 338 Core Set (custom panel)


title: Patient 320 Core Set (cancer panel)


title: Patient 330 Core Set (custom panel)


title: Patient 319 Core Set (cancer panel)


title: Patient 318 Core Set (cancer panel)


title: Patient 305 Core Set (custom panel)


title: Patient 322 Core Set (custom panel)


title: Patient 314 Core Set (custom panel)


title: Patient 317 Core Set (cancer panel)


title: Patient 016 Core Set (custom panel)


title: Patient 316 Core Set (cancer panel)


title: Patient 297 Core Set (custom panel)


title: Patient 315 Core Set (cancer panel)


title: Patient 369 Core Set (custom panel)


title: Patient 313 Core Set (cancer panel)


title: Patient 354 Core Set (custom panel)


title: Patient 312 Core Set (cancer panel)


title: Patient 329 Core Set (custom panel)


title: Patient 311 Core Set (cancer panel)


title: Patient 310 Core Set (cancer panel)


title: Patient 346 Core Set (custom panel)


title: Patient 313 Core Set (custom panel)


title: Patient 308 Core Set (cancer panel)


title: Patient 304 Core Set (custom panel)


title: Patient 321 Core Set (custom panel)


title: Patient 305 Core Set (cancer panel)


title: Patient 314 Core Set (cancer panel)


title: Patient 337 Core Set (custom panel)


title: Patient 306 Core Set (cancer panel)


title: Patient 304 Core Set (cancer panel)


title: Patient 303 Core Set (cancer panel)


title: Patient 008 Core Set (custom panel)


title: Patient 296 Core Set (custom panel)


title: Patient 374 Core Set (custom panel)


title: Patient 361 Core Set (custom panel)


title: Patient 299 Core Set (cancer panel)


title: Patient 302 Core Set (cancer panel)


title: Patient 300 Core Set (cancer panel)


title: Patient 345 Core Set (custom panel)


title: Patient 353 Core Set (custom panel)


title: Patient 336 Core Set (custom panel)


title: Patient 298 Core Set (cancer panel)


title: Patient 320 Core Set (custom panel)


title: Patient 297 Core Set (cancer panel)


title: Patient 312 Core Set (custom panel)


title: Patient 303 Core Set (custom panel)


title: Patient 295 Core Set (custom panel)


title: Patient 294 Core Set (cancer panel)


title: Patient 295 Core Set (cancer panel)


title: Patient 360 Core Set (custom panel)


title: Patient 368 Core Set (custom panel)


title: Patient 293 Core Set (cancer panel)


title: Patient 291 Core Set (cancer panel)


title: Patient 352 Core Set (custom panel)


title: Patient 292 Core Set (cancer panel)


title: Patient 296 Core Set (cancer panel)


title: Patient 290 Core Set (cancer panel)


title: Patient 335 Core Set (custom panel)


title: Patient 289 Core Set (cancer panel)


title: Patient 319 Core Set (custom panel)


title: Patient 288 Core Set (cancer panel)


title: Patient 327 Core Set (custom panel)


title: Patient 287 Core Set (cancer panel)


title: Patient 311 Core Set (custom panel)


title: Patient 286 Core Set (cancer panel)


title: Patient 284 Core Set (cancer panel)


title: Patient 285 Core Set (cancer panel)


title: Patient 302 Core Set (custom panel)


title: Patient 294 Core Set (custom panel)


title: Patient 283 Core Set (custom panel)


title: Patient 291 Core Set (custom panel)


title: Patient 283 Core Set (cancer panel)


title: Patient 282 Core Set (cancer panel)


title: Patient 259 Core Set (custom panel)


title: Patient 281 Core Set (cancer panel)


title: Patient 243 Core Set (custom panel)


title: Patient 290 Core Set (custom panel)


title: Patient 282 Core Set (custom panel)


title: Patient 279 Core Set (cancer panel)


title: Patient 276 Core Set (cancer panel)


title: Patient 275 Core Set (cancer panel)


title: Patient 278 Core Set (cancer panel)


title: Patient 280 Core Set (cancer panel)


title: Patient 274 Core Set (cancer panel)


title: Patient 266 Core Set (custom panel)


title: Patient 274 Core Set (custom panel)


title: Patient 258 Core Set (custom panel)


title: Patient 250 Core Set (custom panel)


title: Patient 277 Core Set (cancer panel)


title: Patient 273 Core Set (cancer panel)


title: Patient 272 Core Set (cancer panel)


title: Patient 269 Core Set (cancer panel)


title: Patient 270 Core Set (cancer panel)


title: Patient 271 Core Set (cancer panel)


title: Patient 268 Core Set (cancer panel)


title: Patient 228 Core Set (custom panel)


title: Patient 265 Core Set (cancer panel)


title: Patient 220 Core Set (custom panel)


title: Patient 235 Core Set (custom panel)


title: Patient 206 Core Set (custom panel)


title: Patient 289 Core Set (custom panel)


title: Patient 213 Core Set (custom panel)


title: Patient 281 Core Set (custom panel)


title: Patient 242 Core Set (custom panel)


title: Patient 273 Core Set (custom panel)


title: Patient 264 Core Set (cancer panel)


title: Patient 263 Core Set (cancer panel)


title: Patient 261 Core Set (cancer panel)


title: Patient 257 Core Set (custom panel)


title: Patient 262 Core Set (cancer panel)